← Back to Search

Immunotherapy

Nivolumab + BMS-986205 for Melanoma

Phase 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose to 30 days following last dose (up to approximately 25 months)
Awards & highlights

Study Summary

The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated

Eligible Conditions
  • Melanoma
  • Skin Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose to 30 days following last dose (up to approximately 25 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose to 30 days following last dose (up to approximately 25 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Experiencing Adverse Events

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Nivolumab + BMS-986205Experimental Treatment2 Interventions
Specified dose on specified day. Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion
Group II: Nivolumab + PlaceboActive Control2 Interventions
Specified dose on specified day Participants will no longer receive BMS-986205 Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Linrodostat
Not yet FDA approved
Nivolumab
FDA approved

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,646 Previous Clinical Trials
4,131,123 Total Patients Enrolled
177 Trials studying Melanoma
57,465 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
2017. "An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03329846.
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top